Crescent Park Management L.P. Has $13.28 Million Position in Cellebrite DI Ltd. $CLBT

Key Points

• Crescent Park Management L.P. reduced its holdings in Cellebrite DI Ltd. by 63.3%, selling over 1.1 million shares and owning approximately 683,411 shares, valuing its stake at around $13.3 million.
• Analysts from firms such as JPMorgan Chase & Co. and Needham & Company issued target price reductions for Cellebrite DI, with an average consensus target price now at $22.40.
• Cellebrite DI reported a positive earnings surprise with an EPS of $0.12 for the quarter, which exceeded analyst expectations, and revenue increased 18.4% year-over-year, reaching $113.28 million.

Crescent Park Management L.P. lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 63.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 683,411 shares of the company's stock after selling 1,179,071 shares during the quarter. Cellebrite DI accounts for approximately 6.2% of Crescent Park Management L.P.'s investment portfolio, making the stock its 5th biggest position. Crescent Park Management L.P. owned about 0.29% of Cellebrite DI worth $13,279,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CLBT. Assetmark Inc. bought a new position in Cellebrite DI during the 1st quarter worth $33,000. Catalyst Capital Advisors LLC bought a new position in shares of Cellebrite DI in the 1st quarter worth about $51,000. Gen Wealth Partners Inc bought a new position in shares of Cellebrite DI in the 4th quarter worth about $85,000. NewEdge Advisors LLC raised its position in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after acquiring an additional 3,352 shares in the last quarter. Finally, JT Stratford LLC bought a new position in shares of Cellebrite DI in the 1st quarter worth about $209,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on CLBT. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Needham & Company LLC cut their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Finally, Lake Street Capital cut their price target on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Stock Performance

CLBT traded up $0.34 during trading on Thursday, reaching $16.81. The stock had a trading volume of 950,317 shares, compared to its average volume of 1,668,139. The stock has a market cap of $4.02 billion, a PE ratio of -22.10, a PEG ratio of 2.87 and a beta of 1.27. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The business has a 50-day moving average of $14.96 and a 200-day moving average of $17.33.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the business posted $0.10 earnings per share. The company's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.